Biopharmaceutical Sciences: M.S., BChE 4+1

The Biopharmaceutical Sciences Master’s Program and the 4+1 (BChE/MS) Program, focused on Bioprocess Development, are built on a collaborative and adaptive educational model that engages leading academic, industrial, and government scientists. This informed training uses industry practice and expertise to create a strengthened pipeline that provides students with a holistic understanding of the biopharmaceutical industry, its regulatory frameworks, and the evolution of the industry as it moves into the future.

The program incorporates a unique model for integrated, 15-month internships in both the MS and 4+1 BChE/MS degree pathways, in concert with key industry partners that have partnered with UD. More broadly, the program leverages UD’s unique position at the intersection of the Greater Philadelphia, New York/New Jersey, and the Capital Region biopharma/biotech hubs, as well as UD’s leadership within the National Institute for Innovation in Manufacturing of Biopharmaceuticals (NIIMBL).

The program was built via collaboration with international leaders in biopharma and government to create a future-facing model for training and retraining scientists in the biopharmaceutical industry. The MS in Biopharmaceutical Sciences consists of 30 credit hours of graduate-level coursework and an integrated internship, completed over 15 months. 4+1 BChE/MS students have the opportunity to complete the traditional four-year bachelor’s program plus the Biopharmaceutical Sciences master’s program in one additional (+1) year.

Note to international applicants:

Due to the online course structure of the MS Biopharmaceutical program, it does not meet the F-1 or J-1 in-person coursework regulations for a full course of study. International Students are not eligible for an I-20 or DS-2019 to participate in this program on an F-1 or J-1 Student visa.

Application Deadlines